Note 10 - Shareholders' Equity |
6 Months Ended | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 | |||||||||||||||||||||||||||||||||
| Notes to Financial Statements | |||||||||||||||||||||||||||||||||
| Stockholders' Equity Note Disclosure [Text Block] |
Authorized capital stock
The Company has authorized share capital of an unlimited number of voting common shares and the shares do not have a stated par value.
Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to one vote per share at the Company's annual general meeting and any special meeting.
Equity issued during the six months ended June 30, 2021
During the six months ended June 30, 2021, 40,000 common shares were issued upon the exercise of options for gross proceeds of $244,000 with an aggregate intrinsic value of $132,000 and warrants were exercised.
Equity issued during the six months ended June 30, 2020
On February 13, 2020, we issued and sold an aggregate of 2,125,000 common shares in a public, underwritten offering at a public offering price of $4.00 per share. As a result of the offering, we received gross proceeds of $8.5 million, which resulted in net proceeds to us of approximately $7.7 million, after deducting the underwriting discount and offering expenses.
During the six months ended June 30, 2020, 7,200 common shares were issued upon the exercise of options for gross proceeds of $16,000 and no warrants were exercised.
Shares reserved
Common shares reserved for future issuance are as follows:
|
||||||||||||||||||||||||||||||||